Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biostar Pharma Appoints New CFO
Mr Chen has replaced Elaine Zhao, who resigned effective at the close of business on June 30, 2010. Most recently, Mr Chen was an independent advisor engaged in
Mr Chen has replaced Elaine Zhao, who resigned effective at the close of business on June 30, 2010. Most recently, Mr Chen was an independent advisor engaged in
AZX100 clinical trial is conducted to study the ongoing safety of AZX100. Additionally, Capstone is expected to evaluate the quality of the clinical trial dataset in order to
Earlier, Dr Glenn was the chief scientific officer and founder of IOMAI Corporation (now Intercell), an associate in international health at Johns Hopkins University’s School of Public Health
Biomagnetics plans to release the technology, initially targeting cholera and tuberculosis, into the public sector upon completion of the prior work. Under the agreement, the scientific and engineering
Takeda Pharma said that Rozerem is for the treatment of insomnia. It works by selectively targeting two melatonin receptors in the brain, MT1 and MT2. Earlier, in July
AstraZeneca and MRC Technology are expected to combine up to 100,000 compounds from AstraZeneca’s collection with around 50,000 from MRC, where MRC is expected to screen the the
With the acquisition, Brenntag is expected to get access to an established distribution network active in nine countries with growth potential. EAC Industrial Ingredients holds an important market
Ablynx said that IWT grant will help the company to accelerate ALX-0171 pre-clinical development programme for the treatment of respiratory syncytial virus (RSV) infections. In the trial, ALX-0171
APP Pharmaceuticals said that its heparin products benefit from carefully designed packaging and labels, which helps in preventing medical errors by helping physicians and clinicians deliver the right
Pixantrone is used for the treatment of relapsed or refractory, aggressive non-Hodgkin’s lymphoma (NHL). CTI is expected to file the MAA later this year. The pediatric program is